Company Overview

Founded in 2014 as a wholly owned subsidiary of Kelun Group and affiliated company of Kelun-Biotech, KLUS Pharma is committed to the discovery and development of innovative biotherapeutics. Our top priority is to address the unmet needs of patients suffering from cancer, cardiovascular disease, autoimmune disease, and other severe disorders due to lack of effective treatment options. Utilizing our innovative technology platforms for monoclonal antibodies, bi-specific antibodies, and Antibody-Drug Conjugates (ADCs), we have advanced multiple biologic programs into the clinical stage to treat these debilitating conditions.

 

KLUS Pharma has streamlined antibody discovery and engineering capabilities, which enable a seamless transition from target discovery to product development. Our team of industry experts in immuno-oncology, immunology, and cardiology, can rapidly advance biological drug candidates from bench to market. KLUS Pharma has identified and assessed dozens of therapeutic targets and is currently conducting preclinical and clinical studies for more than 10 antibody-based therapeutics.

 
Mission

KLUS Pharma focuses on the needs of patients lacking effective treatment options and aims to combat life-threatening diseases with the discovery and development of novel and safer antibody-based therapeutics.

 
Timeline

Oct 2019

SKB264 (TROP2 ADC) Phase 1 trial initiated in the US

May 2018

A166 (HER2 ADC) Phase 1 trial initiated in the US

Jan 2018

Department of Translational Medicine established

Sep 2016

Department of Biologics R&D established

Aug 2016

Department of Clinical Research established

Oct 2015

Department of Business Development established

Oct 2014

KLUS Pharma founded

 

©2020 by KLUS Pharma Inc.